Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Serum FGF21 levels were analyzed in 179 individuals belonging to four groups: HIV-1-infected, antiretroviral-treated patients that have developed lipodystrophy (n = 59); HIV-1-infected, antiretroviral-treated patients without lipodystrophy (n = 45); untreated (naive) HIV-1-infected patients (n = 41); and healthy control individuals (n = 34). Serum FGF21 levels were correlated with parameters indicative of altered fat distribution, metabolic and cardiovascular risk, and in relation to HIV-1 infection and antiretroviral treatment regimens. RESULTS: CONCLUSIONS:
FGF21 levels are increased in HIV-1-infected patients, especially in those with lipodystrophy, and this increase is closely associated with insulin resistance, metabolic syndrome and makers of liver damage. Further research will be required to determine whether the increase in FGF21 levels is caused by a compensatory response or resistance to FGF21, and to establish the potential of FGF21 as a biomarker of altered metabolism in HIV-1-infected, antiretroviral-treated patients.
|
Authors | Pere Domingo, José M Gallego-Escuredo, Joan C Domingo, Maria del Mar Gutiérrez, Maria G Mateo, Irene Fernández, Francesc Vidal, Marta Giralt, Francesc Villarroya |
Journal | AIDS (London, England)
(AIDS)
Vol. 24
Issue 17
Pg. 2629-37
(Nov 13 2010)
ISSN: 1473-5571 [Electronic] England |
PMID | 20935553
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- fibroblast growth factor 21
- Fibroblast Growth Factors
|
Topics |
- Adult
- Anthropometry
- Antiretroviral Therapy, Highly Active
- Biomarkers
(metabolism)
- Female
- Fibroblast Growth Factors
(immunology, metabolism)
- HIV Infections
(immunology, metabolism, virology)
- HIV-Associated Lipodystrophy Syndrome
(immunology, metabolism, virology)
- Humans
- Insulin Resistance
(immunology, physiology)
- Liver
(injuries, metabolism, virology)
- Male
- Risk Factors
|